Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints Dr Christopher Rhodes

Will head cardiovascular and metabolic diseaseresearch for the AZ unit

AstraZeneca MedImmune Dr Christopher RhodesAstraZeneca's biologics research and development arm MedImmune has appointed Dr Christopher Rhodes as vice president, cardiovascular and metabolic disease (CVMD) research.

Dr Rhodes will be responsible for developing and growing MedImmune's research base in CVMD in both the US and UK, as well as contributing to the unit's product development goals.

He joins MedImmune from the University of Chicago, where he held a research director's role that covered diabetes, endocrinology and molecular metabolism and nutrition.

In that position he led a large team of researchers focused on molecular mechanisms that control key functions in the pathogenesis of diabetes and obesity.

YongJun Liu, senior vice president of R&D at MedImmune, said: “I am delighted to welcome Dr Rhodes, a world-renowned researcher in the diabetes field, to MedImmune at this extremely exciting time for our Cardiovascular and Metabolic Disease therapeutic area.

“With his wealth of experience, we know he will propel MedImmune to the next level in metabolic disease, guiding our overall CVMD research strategy and driving results to ensure a seamless process for the progression of new drug candidates through the development process, with the ultimate goal of delivering novel medicines to patients.”

10th August 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics